An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer

Junichi Sakamoto, Chikuma Hamada, Mahbubur Rahman, Susumu Kodaira, Katsuki Ito, Hiroaki Nakazato, Yasuo Ohashi, Masayuki Yasutomi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Oral carmofur, either as a single or in combination with other chemotherapeutic agents, has been used as adjuvant chemotherapy for curatively resected colon cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with this cancer. The objective of this study was to perform a reappraisal of randomized clinical trials conducted in this regard. Methods: We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of oral carmofur for curatively resected colon cancer in terms of overall survival (OS) and disease-free survival (DFS). Results: We analyzed individual patient data of three randomized clinical trials, which met the predetermined inclusion criteria. These three trials had a combined total of 2152 patients, carmofur as adjuvant chemotherapy compared with surgery-alone, 5 years follow-up, intention-to-treat-based analytic strategy and similar end points (OS and DFS). In a pooled analysis, 5 year OS rates were 80.4 and 76.4%, and 5 year DFS rates 76.9 and 71.0%, respectively, in carmofur and surgery-alone group. Oral carmofur had significant advantage over surgery-alone in terms of both OS [pooled hazard ratio, 0.82; 95% confidence interval (CI) = 0.68-0.99; P = 0.043] and DFS (pooled hazard ratio, 0.77; 95% CI = 0.65-0.91; P = 0.003). Conclusions: This individual patient-based meta-analysis demonstrated that oral carmofur significantly improves both OS and DFS in patients with curatively resected colon cancers.

Original languageEnglish (US)
Pages (from-to)536-544
Number of pages9
JournalJapanese Journal of Clinical Oncology
Volume35
Issue number9
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Colonic Neoplasms
Meta-Analysis
Disease-Free Survival
Survival
Adjuvant Chemotherapy
Therapeutics
Survival Rate
Randomized Controlled Trials
Confidence Intervals
1-hexylcarbamoyl-5-fluorouracil
Clinical Trials
Neoplasms

Keywords

  • Carmofur
  • Chemotherapy
  • Colorectal cancer
  • Disease-free survival
  • Overall survival
  • Randomized clinical trials

ASJC Scopus subject areas

  • Oncology

Cite this

An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer. / Sakamoto, Junichi; Hamada, Chikuma; Rahman, Mahbubur; Kodaira, Susumu; Ito, Katsuki; Nakazato, Hiroaki; Ohashi, Yasuo; Yasutomi, Masayuki.

In: Japanese Journal of Clinical Oncology, Vol. 35, No. 9, 09.2005, p. 536-544.

Research output: Contribution to journalArticle

Sakamoto, J, Hamada, C, Rahman, M, Kodaira, S, Ito, K, Nakazato, H, Ohashi, Y & Yasutomi, M 2005, 'An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer', Japanese Journal of Clinical Oncology, vol. 35, no. 9, pp. 536-544. https://doi.org/10.1093/jjco/hyi147
Sakamoto, Junichi ; Hamada, Chikuma ; Rahman, Mahbubur ; Kodaira, Susumu ; Ito, Katsuki ; Nakazato, Hiroaki ; Ohashi, Yasuo ; Yasutomi, Masayuki. / An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer. In: Japanese Journal of Clinical Oncology. 2005 ; Vol. 35, No. 9. pp. 536-544.
@article{d441f1a2fa024bd79aaebd87ef66ec05,
title = "An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer",
abstract = "Background: Oral carmofur, either as a single or in combination with other chemotherapeutic agents, has been used as adjuvant chemotherapy for curatively resected colon cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with this cancer. The objective of this study was to perform a reappraisal of randomized clinical trials conducted in this regard. Methods: We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of oral carmofur for curatively resected colon cancer in terms of overall survival (OS) and disease-free survival (DFS). Results: We analyzed individual patient data of three randomized clinical trials, which met the predetermined inclusion criteria. These three trials had a combined total of 2152 patients, carmofur as adjuvant chemotherapy compared with surgery-alone, 5 years follow-up, intention-to-treat-based analytic strategy and similar end points (OS and DFS). In a pooled analysis, 5 year OS rates were 80.4 and 76.4{\%}, and 5 year DFS rates 76.9 and 71.0{\%}, respectively, in carmofur and surgery-alone group. Oral carmofur had significant advantage over surgery-alone in terms of both OS [pooled hazard ratio, 0.82; 95{\%} confidence interval (CI) = 0.68-0.99; P = 0.043] and DFS (pooled hazard ratio, 0.77; 95{\%} CI = 0.65-0.91; P = 0.003). Conclusions: This individual patient-based meta-analysis demonstrated that oral carmofur significantly improves both OS and DFS in patients with curatively resected colon cancers.",
keywords = "Carmofur, Chemotherapy, Colorectal cancer, Disease-free survival, Overall survival, Randomized clinical trials",
author = "Junichi Sakamoto and Chikuma Hamada and Mahbubur Rahman and Susumu Kodaira and Katsuki Ito and Hiroaki Nakazato and Yasuo Ohashi and Masayuki Yasutomi",
year = "2005",
month = "9",
doi = "10.1093/jjco/hyi147",
language = "English (US)",
volume = "35",
pages = "536--544",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer

AU - Sakamoto, Junichi

AU - Hamada, Chikuma

AU - Rahman, Mahbubur

AU - Kodaira, Susumu

AU - Ito, Katsuki

AU - Nakazato, Hiroaki

AU - Ohashi, Yasuo

AU - Yasutomi, Masayuki

PY - 2005/9

Y1 - 2005/9

N2 - Background: Oral carmofur, either as a single or in combination with other chemotherapeutic agents, has been used as adjuvant chemotherapy for curatively resected colon cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with this cancer. The objective of this study was to perform a reappraisal of randomized clinical trials conducted in this regard. Methods: We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of oral carmofur for curatively resected colon cancer in terms of overall survival (OS) and disease-free survival (DFS). Results: We analyzed individual patient data of three randomized clinical trials, which met the predetermined inclusion criteria. These three trials had a combined total of 2152 patients, carmofur as adjuvant chemotherapy compared with surgery-alone, 5 years follow-up, intention-to-treat-based analytic strategy and similar end points (OS and DFS). In a pooled analysis, 5 year OS rates were 80.4 and 76.4%, and 5 year DFS rates 76.9 and 71.0%, respectively, in carmofur and surgery-alone group. Oral carmofur had significant advantage over surgery-alone in terms of both OS [pooled hazard ratio, 0.82; 95% confidence interval (CI) = 0.68-0.99; P = 0.043] and DFS (pooled hazard ratio, 0.77; 95% CI = 0.65-0.91; P = 0.003). Conclusions: This individual patient-based meta-analysis demonstrated that oral carmofur significantly improves both OS and DFS in patients with curatively resected colon cancers.

AB - Background: Oral carmofur, either as a single or in combination with other chemotherapeutic agents, has been used as adjuvant chemotherapy for curatively resected colon cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with this cancer. The objective of this study was to perform a reappraisal of randomized clinical trials conducted in this regard. Methods: We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of oral carmofur for curatively resected colon cancer in terms of overall survival (OS) and disease-free survival (DFS). Results: We analyzed individual patient data of three randomized clinical trials, which met the predetermined inclusion criteria. These three trials had a combined total of 2152 patients, carmofur as adjuvant chemotherapy compared with surgery-alone, 5 years follow-up, intention-to-treat-based analytic strategy and similar end points (OS and DFS). In a pooled analysis, 5 year OS rates were 80.4 and 76.4%, and 5 year DFS rates 76.9 and 71.0%, respectively, in carmofur and surgery-alone group. Oral carmofur had significant advantage over surgery-alone in terms of both OS [pooled hazard ratio, 0.82; 95% confidence interval (CI) = 0.68-0.99; P = 0.043] and DFS (pooled hazard ratio, 0.77; 95% CI = 0.65-0.91; P = 0.003). Conclusions: This individual patient-based meta-analysis demonstrated that oral carmofur significantly improves both OS and DFS in patients with curatively resected colon cancers.

KW - Carmofur

KW - Chemotherapy

KW - Colorectal cancer

KW - Disease-free survival

KW - Overall survival

KW - Randomized clinical trials

UR - http://www.scopus.com/inward/record.url?scp=27644586383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644586383&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyi147

DO - 10.1093/jjco/hyi147

M3 - Article

C2 - 16155120

AN - SCOPUS:27644586383

VL - 35

SP - 536

EP - 544

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

ER -